0001493152-24-030372.txt : 20240806 0001493152-24-030372.hdr.sgml : 20240806 20240806084214 ACCESSION NUMBER: 0001493152-24-030372 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240806 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InspireMD, Inc. CENTRAL INDEX KEY: 0001433607 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262123838 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35731 FILM NUMBER: 241177244 BUSINESS ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 BUSINESS PHONE: (888) 776-6804 MAIL ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 FORMER COMPANY: FORMER CONFORMED NAME: Saguaro Resources, Inc. DATE OF NAME CHANGE: 20080428 8-K 1 form8-k.htm
false 0001433607 0001433607 2024-08-06 2024-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 6, 2024

 

InspireMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35731   26-2123838

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

4 Menorat Hamaor St.

Tel Aviv, Israel

   6744832
(Address of Principal Executive Offices)   (Zip Code)

 

(888) 776-6804

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition

 

On August 6, 2024, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the three and six months ended June 30, 2024. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
99.1   Press release, dated August 6, 2024 (furnished herewith pursuant to Item 2.02)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSPIREMD, INC.
     
Date: August 6, 2024 By: /s/ Craig Shore
  Name: Craig Shore
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

InspireMD Reports Second Quarter 2024 Financial Results and Provides

Business Update

 

- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –

 

- On track to submit a Premarket Approval (PMA) application to the FDA this quarter -

 

- Raised gross proceeds of $17.9 million from full exercise of Series H warrants triggered by announcement of C-GUARDIANS data -

 

—

 

Management to host investor conference call today, August 6th, at 8:30am ET

 

—

 

Tel Aviv, Israel and Miami, FL — August 6, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the second quarter ended June 30, 2024.

 

Second Quarter 2024 and Recent Developments:

 

●Announced one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime demonstrating a primary endpoint event rate of 1.95% through one year, the lowest such event rate for any carotid stent or embolic protection device pivotal clinical trial.

 

●Announced the full exercise of 12.9 million Series H warrants issued pursuant to the transformational public financing of up to $113.6 million announced in May 2023. The Series H warrants were exercised primarily into pre-funded warrants and resulted in gross proceeds of $17.9 million, or $16.9 million after fees.

 

●Generated second quarter 2024 CGuard EPS revenue of $1.74 million, an increase of 5.4% over the second quarter of 2023, on 2,969 CGuard stents sold, up nearly 6% over the second quarter of 2023.

 

●Engaged with a leading MedTech search firm, The Mullings Group, to accelerate build-out of world-class operations and commercial teams in the United States.

 

●Announced completion of enrollment in groundbreaking CREST-2 clinical trial, with 23 patients in the stenting arm treated with CGuard, the only investigational device allowed by FDA for inclusion in the trial.

 

●Advanced preparation activities for initiation of the CGUARDIANS II Transcarotid Arterial Revascularization (TCAR) clinical trial in the back half of 2024.

 

 

 

 

 

Marvin Slosman, CEO of InspireMD, commented: “The clear highlight since our last quarterly report was the announcement of best in class one-year outcomes data from our pivotal C-GUARDIANS clinical trial of the CGuard Carotid Stent System, which was designed to support a Premarket Approval (PMA) application to FDA later this year. The data demonstrated a primary endpoint event rate of 1.95% through one year, the lowest such rate for any carotid stent or embolic protection device pivotal clinical trial, thus adding to the significant body of data that we have compiled demonstrating the outstanding performance of CGuard both short- and long-term. With these results in hand, we intend to proceed with a PMA application in the back half of this year while continuing to build out a world-class US commercial infrastructure in anticipation of FDA approval in the first half of 2025.

 

“In parallel, we continued to advance development of our pipeline of carotid intervention and stroke prevention tools, including our SwitchGuard NPS TCAR solution, and we remain on track to initiate our CGUARDIANS II clinical trial in the back half of this year. By uniquely developing solution sets for both CAS and TCAR utilizing our best-in-class CGuard Prime stent implant, we believe we are well positioned for the ongoing paradigm shift toward an endovascular ‘stent first’ approach. I am very pleased with our continued progress and look forward to a productive back half of the year,” Mr. Slosman concluded.

 

Financial Results for the Second Quarter ended June 30, 2024

 

For the three months ended June 30, 2024, revenue increased by $90,000, or 5.4%, to $1,739,000, from $1,649,000 for the three months ended June 30, 2023. This increase was driven by growth in existing and new markets, partially offset by a reduction in clinical trial revenue driven by the conclusion of C-GUARDIANS enrollment in June 2023.

 

For the three months ended June 30, 2024, gross profit (revenue less cost of revenues) decreased by $160,000, or 32.6%, to $331,000, from $491,000 during the three months ended June 30, 2023. This decrease in gross profit resulted from an increase in material and labor costs mainly due to compensation expense for new and current employees, higher sales volume, additional space to build capacity for anticipated increased volume requirements and additional training expenses offset by an increase in revenues. Gross margin (gross profits as a percentage of revenue) decreased to 19.0% during the three months ended June 30, 2024, from 29.8% during the three months ended June 30, 2023, driven by the factors mentioned above.

 

Total operating expenses for the second quarter of 2024 were $8,591,000, an increase of $2,785,000, or 48.0%, compared to $5,806,000 for the second quarter of 2023. This increase was primarily due to an increase in compensation and development expenses with the vast majority being non-cash share-based compensation-related expenses.

 

Net loss for the second quarter of 2024 totaled $7,909,000, or $0.22 per basic and diluted share, compared to a net loss of $5,077,000, or $0.24 per basic and diluted share, for the same period in 2023.

 

As of June 30, 2024, cash, cash equivalents and marketable securities were $47.2 million compared to $39.0 million as of December 31, 2023. This includes the full exercise of Series H Warrants, raising gross proceeds of $17.9 million, related to the announcement of one-year follow up from the C-GUARDIANS pivotal trial.

 

Financial Results for the Six Months ended June 30, 2024

 

For the six months ended June 30, 2024, revenue increased by $362,000, or 12.5%, to $3,250,000, from $2,888,000 for the six months ended June 30, 2023. This sales increase was due to growth in existing and new markets, partially offset by a reduction in clinical trial revenue due to the completion of C-GUARDIANS enrollment in June 2023.

 

 

 

 

 

For the six months ended June 30, 2024, gross profit (revenue less cost of revenues) decreased by 27.9%, or $241,000, to $623,000, compared to $864,000 for the same period in 2023. This decrease in gross profit resulted from an increase in material and labor costs mainly due to compensation expense for new and current employees, higher sales volume, additional space to build capacity for anticipated increased volume requirements and additional training expenses offset by an increase of the revenues.

 

Total operating expenses for the six months ended June 30, 2024, were $16,297,000, an increase of $5,737,000, or 54.3% compared to $10,560,000 for the six months ended June 30, 2023. This increase was primarily due to an increase in compensation and development expenses with the vast majority being non-cash share-based compensation-related expenses.

 

Net loss for the six months ended June 30, 2024, totaled $14,941,000, or $0.43 per basic and diluted share, compared to a net loss of $9,333,000, or $0.64 per basic and diluted share, for the six months ended June 30, 2023.

 

Conference Call and Webcast Details

 

Management will host a conference call at 8:30AM ET today, August 6, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Tuesday, August 6th at 8:30 a.m. ET

 

  Domestic: 1-800-445-7795
  International: 1-785-424-1699
  Conference ID: IMD2Q24
  Webcast: Webcast Link – Click Here

 

About InspireMD, Inc.

 

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.

 

We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

 

 

 

 

 

Forward-looking Statements

 

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including revenue growth. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Investor Contacts:

 

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

craigs@inspiremd.com

 

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390

chuck@lifesciadvisors.com

 

investor-relations@inspiremd.com

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS(1)

(U.S. dollars in thousands, except per share data)

 

   Three months ended June 30,   Six months ended June 30, 
   2024   2023   2024   2023 
                 
Revenues  $1,739   $1,649   $3,250   $2,888 
Cost of revenues   1,408    1,158    2,627    2,024 
                     
Gross Profit   331    491    623    864 
                     
Operating Expenses:                    
Research and development   3,401    1,993    6,026    3,836 
Selling and marketing   1,445    892    2,682    1,680 
General and administrative   3,745    2,921    7,589    5,044 
                     
Total operating expenses   8,591    5,806    16,297    10,560 
                     
Loss from operations   (8,260)   (5,315)   (15,674)   (9,696)
                     
Financial income   351    238    733    363 
                     
Net Loss  $(7,909)  $(5,077)  $(14,941)  $(9,333)
                     
Net loss per share – basic and diluted  $(0.22)  $(0.24)  $(0.43)  $(0.64)
                     
Weighted average number of shares of common stock used in computing net loss per share – basic and diluted   35,877,926    21,074,187    35,060,451    14,619,622 

 

 

 

 

 

CONSOLIDATED BALANCE SHEETS(2)

(U.S. dollars in thousands)

 

   June 30, 2024   December 31, 2023 
         
ASSETS        
Current Assets:          
Cash and cash equivalents  $28,385   $9,640 
Marketable securities   18,778    29,383 
Accounts receivable:          
Trade, net   1,307    1,804 
Other   450    648 
Prepaid expenses   717    578 
Inventory   2,206    2,106 
           
Total current assets   51,843    44,159 
           
Non-current assets:          
Property, plant and equipment, net   1,595    1,060 
Operating lease right of use assets   1,257    1,473 
Funds in respect of employee rights upon retirement   964    951 
           
Total non-current assets   3,816    3,484 
           
Total assets  $55,659   $47,643 

 

 
 

 

 

   June 30, 2024   December 31, 2023 
         
LIABILITIES AND EQUITY          
Current liabilities:          
Accounts payable and accruals:          
Trade   927    939 
Other   6,038    5,081 
           
Total current liabilities   6,965    6,020 
           
Long-term liabilities:          
Operating lease liabilities   786    1,038 
Liability for employees rights upon retirement   1,145    1,084 
Total long-term liabilities   1,931    2,122 
           
Total liabilities   8,896    8,142 
           
Equity:          
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at June 30, 2024 and December 31, 2023; 25,196,479 and 21,841,215 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively   3    2 
Preferred C shares, par value $0.0001 per share;
1,172,000 shares authorized at June 30, 2024 and December 31, 2023; 1,718 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		   *    * 
Additional paid-in capital   283,202    261,000 
Accumulated deficit   (236,442)   (221,501)
           
Total equity   46,763    39,501 
           
Total liabilities and equity  $55,659   $47,643 

 

 
 

 

 

(1) All 2024 financial information is derived from the Company’s 2024 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2023 financial information is derived from the Company’s 2023 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.

 

(2) All June 30, 2024, financial information is derived from the Company’s 2024 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2023 financial information is derived from the Company’s 2023 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2023 filed with the Securities

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 nspr-20240806.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 nspr-20240806_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 nspr-20240806_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 06, 2024
Entity File Number 001-35731
Entity Registrant Name InspireMD, Inc.
Entity Central Index Key 0001433607
Entity Tax Identification Number 26-2123838
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Menorat Hamaor St.
Entity Address, City or Town Tel Aviv
Entity Address, Country IL
Entity Address, Postal Zip Code 6744832
City Area Code (888)
Local Phone Number 776-6804
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NSPR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inspiremd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm nspr-20240806.xsd nspr-20240806_lab.xml nspr-20240806_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NSPR", "nsuri": "http://inspiremd.com/20240806", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "nspr-20240806.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "nspr-20240806_lab.xml" ] }, "presentationLink": { "local": [ "nspr-20240806_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://inspiremd.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-030372-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-030372-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001433607 2024-08-06 2024-08-06 iso4217:USD shares iso4217:USD shares false 0001433607 8-K 2024-08-06 InspireMD, Inc. DE 001-35731 26-2123838 4 Menorat Hamaor St. Tel Aviv IL 6744832 (888) 776-6804 false false false false Common Stock, par value $0.0001 per share NSPR NASDAQ false